# Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

> **NCT03672318** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma
- Immune System Diseases

## Interventions

- **DRUG:** CAR138 T Cells

## Key facts

- **NCT ID:** NCT03672318
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-14
- **Primary completion:** 2024-10-16
- **Final completion:** 2039-08-18
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672318, "Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03672318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*